ISSN 2413‑1261 

A Novel Synthetic Route for 1,2'-Binaphthalene Derivative, Analogues of Isodiospyrin

dc.contributor.authorBacherikov, Valeriy A
dc.date.accessioned2023-03-15T14:59:08Z
dc.date.available2023-03-15T14:59:08Z
dc.date.issued2003
dc.descriptionBacherikov Valeriy A. A Novel Synthetic Route for 1,2'-Binaphthalene Derivative, Analogues of Isodiospyrin / Bacherikov Valeriy A., Kamesh Rastogi // Chinese pharmaceutical Journal. – 2003. – Vol. 4. – P. 247-256.en_US
dc.description.abstractA new synthetic route for l,2’-binaphthalenes was developed. 4,5,8’-Trimethoxy-2,3’-dimeth- yl-[l,2’]-binaphthalenyl-l’-ol (20) was synthesized by aryl-aryl coupling of the prefixed aryloxy- methyl-aryl intermediate followed by reductive cleavage of the ethereal bridge. Compound 20 was further oxidized with Fremy’s salt to give 4,5,8’-trimethoxy-2,3’-dimethyl-[l,2’]-binaphthalenyl- l’,4’-dione (21). Preliminary studies showed that compound 21 was active against Leishmania mexicana (LV78) promastigotes, but was inactive against the cell growth of a variety of human tu-mor cell lines.en_US
dc.identifier.citationBacherikov Valeriy A. A Novel Synthetic Route for 1,2'-Binaphthalene Derivative, Analogues of Isodiospyrin / Bacherikov Valeriy A., Kamesh Rastogi // Chinese pharmaceutical Journal. – 2003. – Vol. 4. – P. 247-256.en_US
dc.identifier.urihttps://hdl.handle.net/11300/23973
dc.language.isoenen_US
dc.subject1.2'-Binsphthalenesen_US
dc.subject1,2'-Bisnaphthoquinonesen_US
dc.subjectSynthesisen_US
dc.subjectAntileishmanial activityen_US
dc.subjectL. mexicanaen_US
dc.subjectPromastigoteen_US
dc.titleA Novel Synthetic Route for 1,2'-Binaphthalene Derivative, Analogues of Isodiospyrinen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Chinese Pharmaceutical Journal 2003, 55, 247-256.pdf
Size:
15.35 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: